Abstract
An animal model was used to assess the efficacy of levofloxacin (LVFX) incorporated into albumin (ALB)-sealed Dacron (LVFX-ALB) graft for the prevention of vascular graft infections caused by Staphylococcus aureus. Under general anesthetic, an interposition graft was placed into dog carotid artery. On completion of the operation, 0.1 ml of normal saline containing 107 colony-forming units (CFU) of a slime-producing S. aureus was inoculated directly onto the graft. After 1 day, the samples were sterilely harvested. The antibacterial activity of LVFX into the LVFX-ALB graft was evaluated by colony counting in bacterial cultures and by the fluorescent antibody method staining bacteria adhesion to the grafts. LVFX-ALB grafts had a lower infection rate than the control grafts (1/4, 102 CFU vs 4/4, 1.50 X 105 ± 1.38 X 105 CFU (mean ± SE)). In an immunostaining study, LVFX-ALB grafts had small fluorescent areas showing S. aureus adhesion, while fluorescence was observed over the entire surface of the control grafts. Therefore, LVFX- ALB presumably had a bactericidal action and adhesive prevention against inoculated S. aureus. LVFX-ALB may be useful in preventing graft infections during and immediately after vascular reconstruction.
| Original language | English |
|---|---|
| Pages (from-to) | 317-321 |
| Number of pages | 5 |
| Journal | Microbiology and Immunology |
| Volume | 43 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 01-01-1999 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Microbiology
- Immunology
- Virology
Cite this
}
Prophylaxis of local vascular graft infection with levofloxacin incorporated into albumin-sealed Dacron graft (LVFX-ALB graft). / Osada, Takashi; Yamamura, Keiko; Fujimoto, Katsuhiro; Mizuno, Keisuke; Sakurai, Tsunehisa; Ohta, Michio; Nabeshima, Toshitaka.
In: Microbiology and Immunology, Vol. 43, No. 4, 01.01.1999, p. 317-321.Research output: Contribution to journal › Article
TY - JOUR
T1 - Prophylaxis of local vascular graft infection with levofloxacin incorporated into albumin-sealed Dacron graft (LVFX-ALB graft)
AU - Osada, Takashi
AU - Yamamura, Keiko
AU - Fujimoto, Katsuhiro
AU - Mizuno, Keisuke
AU - Sakurai, Tsunehisa
AU - Ohta, Michio
AU - Nabeshima, Toshitaka
PY - 1999/1/1
Y1 - 1999/1/1
N2 - An animal model was used to assess the efficacy of levofloxacin (LVFX) incorporated into albumin (ALB)-sealed Dacron (LVFX-ALB) graft for the prevention of vascular graft infections caused by Staphylococcus aureus. Under general anesthetic, an interposition graft was placed into dog carotid artery. On completion of the operation, 0.1 ml of normal saline containing 107 colony-forming units (CFU) of a slime-producing S. aureus was inoculated directly onto the graft. After 1 day, the samples were sterilely harvested. The antibacterial activity of LVFX into the LVFX-ALB graft was evaluated by colony counting in bacterial cultures and by the fluorescent antibody method staining bacteria adhesion to the grafts. LVFX-ALB grafts had a lower infection rate than the control grafts (1/4, 102 CFU vs 4/4, 1.50 X 105 ± 1.38 X 105 CFU (mean ± SE)). In an immunostaining study, LVFX-ALB grafts had small fluorescent areas showing S. aureus adhesion, while fluorescence was observed over the entire surface of the control grafts. Therefore, LVFX- ALB presumably had a bactericidal action and adhesive prevention against inoculated S. aureus. LVFX-ALB may be useful in preventing graft infections during and immediately after vascular reconstruction.
AB - An animal model was used to assess the efficacy of levofloxacin (LVFX) incorporated into albumin (ALB)-sealed Dacron (LVFX-ALB) graft for the prevention of vascular graft infections caused by Staphylococcus aureus. Under general anesthetic, an interposition graft was placed into dog carotid artery. On completion of the operation, 0.1 ml of normal saline containing 107 colony-forming units (CFU) of a slime-producing S. aureus was inoculated directly onto the graft. After 1 day, the samples were sterilely harvested. The antibacterial activity of LVFX into the LVFX-ALB graft was evaluated by colony counting in bacterial cultures and by the fluorescent antibody method staining bacteria adhesion to the grafts. LVFX-ALB grafts had a lower infection rate than the control grafts (1/4, 102 CFU vs 4/4, 1.50 X 105 ± 1.38 X 105 CFU (mean ± SE)). In an immunostaining study, LVFX-ALB grafts had small fluorescent areas showing S. aureus adhesion, while fluorescence was observed over the entire surface of the control grafts. Therefore, LVFX- ALB presumably had a bactericidal action and adhesive prevention against inoculated S. aureus. LVFX-ALB may be useful in preventing graft infections during and immediately after vascular reconstruction.
UR - http://www.scopus.com/inward/record.url?scp=0032929820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032929820&partnerID=8YFLogxK
U2 - 10.1111/j.1348-0421.1999.tb02411.x
DO - 10.1111/j.1348-0421.1999.tb02411.x
M3 - Article
C2 - 10385197
AN - SCOPUS:0032929820
VL - 43
SP - 317
EP - 321
JO - Microbiology and Immunology
JF - Microbiology and Immunology
SN - 0385-5600
IS - 4
ER -